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Friend leukemia virus complex (FV) a induces a rapidly progressive erythroleukemia 
in young or adult mice. FV-induced leukemic splenomegaly occurs 7-14 d  after virus 
inoculation  and persists until death  (30-120 d)  in susceptible mice. In certain  mouse 
strains,  recovery from  leukemia  occurs  14-28  d  after  virus  inoculation  and  confers 
long-lasting protection against repeated FV challenge or relapse of leukemia.  Several 
individual  genes responsible  for resistance/susceptibility  to FV  leukemia  have been 
described  (1). The mouse major histocompatibility complex (H-2) strongly influences 
recovery from established  leukemia  (2,  3).  At  high  virus  doses  (1,500  focus-forming 
units  [FFU]), H-2  b/b mice have a  high incidence of recovery, whereas H-2  a/b and H- 
2  a/a  mice have a  lower incidence of recovery (4).  However, when a  lower virus dose 
(15 FFU)  is given, H-2  b/b and H-2  a/b have a  high incidence of recovery as compared 
to H-2  "/" mice  (4).  The differences  in recovery seen among these  H-2 genotypes are 
due  to  a  gene  (Rfv-1)  located  in  the  H-2D  subregion  (3).  Viral  replication  and 
neoplastic transformation, as measured by spleen focus formation, are quite similar in 
H-2  b/b and H-2  a/b mice (3). The H-2 influence on recovery from FV-induced leukemia 
seems to be associated  with  later  events of FV infection such as the rejection  of FV 
transformed cells. The actual mechanism of rejection is unclear;  however, both anti- 
FV antibodies and anti-FV cytotoxic T  lymphocytes (CTL) are probably required  (5, 
6). 
Our studies were carried out to identify the organs and cell type(s)  responsible for 
the H-2D (Rfv-1) influence on recovery from FV leukemia. The results indicated that 
recovery was not  dependent  on the  H-2 genotype of the  leukemia  cells,  but  instead 
seemed  to be dependent  on effector mechanisms  developed  by nonleukemic  cells of 
the spleen and bone marrow from high recovery H-2  b/b mice. 
Materials  and Methods 
Animals.  C57BL/10Sn (H-2b/b), B10.A (H-2"/"), A.BY (H-2b/b), and A/WySN (H-2  "/") mice 
were purchased from The Jackson Laboratory, Bar Harbor, Maine. Fl hybrids were bred at the 
Rocky Mountain Laboratory, Hamilton, Mont. Mice used in all experiments were between 2 
and 4 mo of age. Mice within experimental groups were sex and age matched. 
i Abbreviations used in this paper: CTL, cytotoxic T lymphocyte(s); FFU, focus-forming units; FV Friend 
leukemia virus complex; FV-B B-tropic strain of Friend virus; Hh, hernopoietic histocompatibility; NK, 
natural killer. 
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Virus.  The  B-tropic strain of Friend virus  (FV-B)  was  obtained from  Dr.  Frank Lilly, 
Department of Genetics, Albert Einstein School  of Medicine, Bronx, N.  Y. The virus stocks 
were prepared in (C57BL/10Sn ×  A.BY)F1 mice and assayed as previously described (4). 
Cell Culture.  Origin of and method of in vitro growth of Y57 (H-2b/b), YA97  (H-2  a/b) and 
AA41  (H-2  a/~) FV-induced erythroleukemia cell lines were  previously described  (7,  8).  For 
tumor challenge experiments, clone 101 of Y57 was used. Clone 101 was obtained by limiting- 
dilution cloning in vitro and  produced  both  the  defective and  helper components of FV. 
Furthermore, it grew rapidly in vivo after intravenous inoculation. 
Recovery Experiments.  Mice were injected with FV and followed  for recovery from palpable 
splenomegaly as previously described (3). 
Irradiation Chimeras.  Recipient mice were given 900 rad of whole body x-irradiation from a 
Maximar type III 250 kV deep therapy x-ray unit (General Electric Co., Medical Systems Div., 
Milwaukee,  Wise.)  delivering 32  rad/min  at  52  cm  from  the  mid-plane of  the  mouse. 
Approximately 4-6 h  postirradiation, the  mice were  reconstituted with  10  ×  106-15 ×  106 
spleen and 5 ×  106 bone marrow cells. These chimeric mice were then rested for 60-90 d before 
use in recovery experiments. 
Neonatal Tolerant Donor Mice.  Neonatal (<24 h of age)  (C57BL/10Sn ×  A.BY)F1 or (B 10.A 
×  A/WySn)Fa mice were inoculated intravenously via the retroorbital vein with  10 X  108-15 
×  10  e spleen and 5 ×  108 bone marrow cells from a (B10.A × A/WySn)F1 donor. 40-60 d after 
tolerance induction, the mice were tested for tolerance by skin grafting with (B 10.A × A.BY)F1 
tail skin grafts.  Mice with viable, intact skin grafts 35 d after grafting were considered tolerant. 
Fetal  Liver  Chimeras.  Fetal  liver  cells  were  obtained  from  15-day-old  (C57BL/10Sn  × 
A.BY)Fx fetuses. Recipient mice received 900 rad and were then reconstituted by intravenous 
inoculation of 20 ×  10  viable fetal liver cells. These chimeras were then rested for 120 d before 
use as experimental mice. 
Anti-Thy-I Complement +  (C')  Treatment.  A rat anti-mouse Thy-1 hybridoma cell line, clone 
31-11 (9), was kindly provided by Dr. Irving  Weissman, Stanford University  School of Medicine, 
Palo Alto, Calif. For elimination of T  lymphocytes, l0  s spleen and bone marrow cells were 
suspended  in  15  ml  of diluent  (phosphate-buffered  balanced salt  solution with  2%  heat 
inactivated fetal calf serum) mixed with 7 ml of anti-Thy-1 hybridoma tissue culture supernate 
and incubated at 37°C for 30 rain. Cells were washed twice with diluent, resuspended in 40 ml 
of diluent, and mixed with 3 ml of absorbed rabbit serum as C' source (5). After a  45-min 
incubation at  37°C, the cells  were washed  three times with diluent. This anti-Thy-1 +  C' 
treatment yielded 60%  of the  viable starting cell  number, eliminated the concanavalin A- 
induced mitogenic response and anti-FV cytotoxic T lymphocyte activity in vitro, whereas it 
enriched  for  lipopolysaccharide-induced mitogenesis.  Furthermore,  pretreatment  of donor 
(C57BL/10Sn ×  A.BY)F1 (H-2b/~ spleen cells with anti-Thy-1 monoelonal antibody plus C' 
before transfer into (B 10.A ×  A.BY)FI (H-28/b) mice prevented a detectable graft versus host 
reaction. 
H-2  Typing.  A  two-stage microcytotoxicity assay  using leukemia cell  absorbed rabbit C' 
and SlCr-labeled targets was used as previously described (5). Anti-H-2 sera were as follows: 
(A/WySn ×  B10.A)F1 anti-C57BL/10Sn (H-2  a anti:H-2  b) and National Institutes of Health 
contract sera D4 (B 10.AKM ×  129)F1 anti-B10.A ((KkD  ~ ×  Kb~D  b~) anti-KkDd). 
Statistical Methods.  Analysis of statistical significance of data was done using the X  2 test  for 
a 2 ×  2 contingency table. 
Results 
H-2-associated  Recovery  from  Leukemia  Is  Transferred  by  Spleen  and  Bone  Marrow 
Cells.  Lethally  irradiated  H-2  b/b  mice  were  reconstituted  with  spleen  and  bone 
marrow cells of the H-2  "/h or H-2  b/b genotype. 8 wk later these mice were inoculated 
with FV and followed for recovery from leukemia. Recipients which received H-2  a/b 
cells had  a  low incidence of recovery, whereas mice reconstituted with  H-2  b/b cells 
had  a  high  incidence of recovery  (Table I).  Thus,  the  H-2  genotype of the  donor 
spleen and bone marrow cells influenced the incidence of recovery, in that donor cells WILLIAM J.  BRITT AND BRUCE  CHESEBRO  1797 
TABLE  I 
Recovery From FV Leukemia after Transfer of Spleen and Bone Marrow Cells into Irradiated Recipients 
Donor genotype*  Irradiated recipient genotype  Virus dose:l:  Recovered/total§ 
H-2  h/h  H-2  b/h  280  27/38 (71%) 
H-2  "/h  H-2  h/b  280  2/16 ( 13%)tl 
Unirradiated control¶ H-2  h/h  280  15/20 (75%) 
Unirradiated control H-2  a/h  280  2/10 (20%) 
H-2  b/b  H-2  h/h  180  14/14 (100%) 
H -2  "/h  H-2 h/b  180  4/23 (17%)11 
Unirradiated control H-2 h/h  180  9/10 (90%) 
Unirradiated control H-2  a/b  180  2/10 (20%) 
H-2  a/a  H-2  a/a  25  1  /  13 (8%) 
H-2  a/b  H-2  a/"  25  14/20 (70%)11 
Unirradiated control H-2  "/a  25  3/10 (30%) 
Unirradiated control H-2  "/h  25  9/9 (100%) 
* Strains of mice used as follows: H-2  b/b == (C57BL/10Sn × A.BY)Fl; H-2 a/b  =  (BI0.A × A.BY)FI; H-2  a/a 
(BI0.A X A/WySn)Fj. 
:~ FFU of FV-B given intravenously. 
§ Number of mice recovering from FV splenomegaly over total number of mice. 
II P < 0.001 for incidence of recovery of chimeras reconstituted with syngeneic spleen and bone marrow cell 
as compared with chimeras reconstituted with semi-allogeneic spleen and bone marrow cells. 
¶ Unirradiated controls were sex- and age-matched mice given virus only. 
from the higher recovery phenotype (H-2  h/b) produced a  higher incidence of recovery 
after adoptive transfer. Because the recipients with the lower recovery incidence had 
received heterozygous H-2  a/b donor cells, it was possible that  the low recovery seen 
b/b  •  -  could have been a result of incompatibility between H-2  a/b donor and H-2  reclptent. 
To examine this possibility, donor cells of H-2  a/b and H-2  ~/" genotypes were compared 
for  their  influence  on  recovery  after  inoculation  into  lethally  irradiated  H-2  ~/" 
recipients. A  lower FV  dose  (25  FFL  0  was  used  to  distinguish  the  higher  recovery 
incidence  of  H-2  a/b  mice  from  that  of H-2  ~/a  mice  (4).  Here,  as  in  the  previous 
experiments, the donor cells from the higher recovery phenotype (in this case H-2  a/b) 
produced a  higher incidence of recovery after transfer (Table I). Thus, the incompat- 
ibility between H-2  "/b donor and H-2  ~/~ recipient did not influence the recovery from 
leukemia. 
Some chimeras were also made using fetal liver as donor tissue. H-2 b/b  fetal liver 
was transferred to irradiated H-2  a/b or H-2 b/b recipients. A  high incidence of recovery 
from  FV  leukemia was  seen  in  both  groups  (Table  II).  Because  the  high  recovery 
phenotype  was  transferable  with  H-2  b/b  fetal  liver cells,  it  would  appear  that  the 
environment  in  which  these  cells matured  in  vivo did  not  alter their  influence on 
recovery from leukemia. 
In all adoptive transfers, the incidence of recovery from FV-induced splenomegaly 
was dependent on the genotype of the donor spleen, bone marrow, or fetal liver cells. 
Because  these  tissues  contained  both  the  primitive  erythroid  cells  susceptible  to 
transformation  by FV  and  cells involved in  immunological effector mechanisms  of 
potential  importance for recovery from  FV leukemia, subsequent  experiments were 
designed  to  distinguish  which  of  these  cell  populations  accounted  for  the  H-2- 
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TABLE  II 
Recovery From FV Leukemia after Transfer of H-2 bib Fetal Liver Cells into 
Irradiated Recipients 
Fetal liver donor  Irradiated recipient genotype*  Recovered/total:)  genotype 
H-2  h/h  H-2  "/b  25/25 (100%) 
H-2 b/h  H-2 b/b  21/21 (100%) 
Unirradiated H-2  ~/b control§  0/8 (0%) 
Unirradiated H-2  h/b control§  10/10 (100%) 
* Strains of mice used as follows:  H-2  h/b =  (C57BL/lOSn ×  A.BY)Fj  and H-2  ~/b = 
(BIO.A  ×  A.BY)F1.  Mice were irradiated and reconstituted with 20 ×  106 viable 
(C57BL/IOSn ×  A.BY)FI  fetal liver cells as described in Materials and Methods. 
:(c Number of mice recovering from FV splenomegaly over total number of experimen- 
tal mice. All mice were given 800 FFU FV-B intravenously. 
§ Unirradiated controls were sex- and age-matched littermates that were given virus 
only. 
TABLE  III 
Resistance of (B IO.A  ×  A.B Y)F1 (H-2 a/b) Mice to Challenge with Congeneic FV-induced Tumors 
Tumor*  Genotype  Recipient:~  Recovered/total§ 
Y57 (clone 101)  H-2  b/b  Normal  5/32 (16%) 
Y57 (clone 101)  H-2  b/b  FV inoculated  9/9 (100%)11 
YA-97  H-2  a/h  Normal  2/23 (9%) 
YA-97  H-2  a/h  FV inoculated  8/8 (100%) H 
AA41  H-2  a/a  Normal  7/34 (20%) 
AA41  H-2  a/~  FV inoculated  14/14 (! 00%)I 
* Tumors established from FV leukemic spleens from (C57BL/lOSn × A.BY)F3 (H-2b/b), (B10.A X A.BY)FI 
(H-2a/~, and B10.A ×  A/WySn (H-2a/a). Median survival time for tumors as follows:  Y57  (clone 101) 
16.1 ±  3.9 d, YA-97  14.5 +  .68 d, and AA41  15.8 +  1.0 d as determined in (B10.A X A.BY)FI H-2  a/b mice 
given 106 viable cells intravenously,  a b  5  6  b  S 
:~ Recipient mice (BI0.A ×  A.BY)FI  H-2 /  received 10  or 10' Y57 (H-2 /h) tumor cells;  10  or 106 YA-97 
a/  5  6  7  a/a  (H-2  h) tumor cells; and  10 , 10' or  10  AA41  (H-2  ) tumor cells intravenously. Data were pooled for 
all  doses  of tumor cells because  no  significant differences among  doses  were  noted.  Recipient  FV- 
inoculated mice were given 280 FFU of FV-B intraperitoneally 10-14 d  before inoculation with FV- 
induced tumors. Normal recipients were age- and sex-matched littermates of FV-inoculated recipients. 
§ Recovered mice over total number of mice inoculated. 
I[ P <  0.001  for incidence of recovery in FV-inoculated mice as compared with normal mice. 
Resistance of (BIO.A  ×  A.BY)F1  (H-2 a/b)  Mice to Challenge  with Congeneic FV-induced 
Tumors.  If the  H-2  genotype  of the  FV  leukemia  cell  determined  the  incidence  of 
recovery,  then  leukemia  cells  of the  high-recovery  H-2  b/b  genotype  could  be  more 
easily rejected than  those of the low-recovery H-2  a/a genotype. To determine  if the H- 
2  genotype  of  FV  leukemia  cells  influenced  their  sensitivity  to  in  vivo  rejection 
mechanisms,  heterozygous (B 10.A ×  A.BY)F1 (H-2  a/b) mice were challenged with cells 
from  three FV  erythroleukemia  lines derived  from  congeneic mice differing only for 
their  H-2  genotype.  All  three  tumors  were  lethal  for  80-90%  of  H-2  a/b  mice  and 
produced  similar mean  survival times  (Table III).  H-2a/bmice were inoculated  intra- 
peritoneally  with  a  dose  of  FV  previously  shown  to  result  in  recovery  from  FV- 
induced  splenomegaly  (4). These  mice were then challenged  with a  lethal number  of 
FV-induced  leukemia cells  10-14 d  after FV  inoculation, a  time at which  these mice WILLIAM J.  BRITT AND BRUCE CHESEBRO  1799 
TABLE  IV 
Recovery From FV Leukemia of Unirradiated (B I O.A  ×  A.B Y)  F1 Given Neonatally 
Tolerant Spleen and Bone Marrow Cells 
Donor*  Recipient:]:  Recovered/total§  P value 
H-2  b/b  H-2  "/b  25/28 (89%) 
Control][  H-2  a/b  3/17 (18%) 
<0.001 
H-2  a/a  H-2  a/b  2/14  (14%) 
Control  H-2  ~/b  2/15 (13%)  >0.1 
* Strain  of mice used  as  follows:  H-2  b/b ~  (C57BL/10  ×  A.BY)Fj;  H-2  a/b =  (BI0.A  × 
A.BY)F1; and H-2  a/a ~= (B10.A × A/WySn)F1. Donor mice were made neonatally tolerant 
as described in Materials and Methods. 
:~ Recipient (B10.A ×  A.BY)FI H-2  a/b mice were given 280 FFU intravenously; 4-6 h later, 
the mice received 35 ×  10%40 ×  10  e viable spleen  and bone marrow cells intravenously 
from tolerant donors. 
§ Number of mice recovering from FV splenomegaly over total number of mice. H-2 typing 
by cytotoxic antibody plus C' of 10 representative recipient mice revealed >90% of cells in 
recipient mice were of the H-2  a/b genotype. 
]l Sex- and age-matched control mice received only virus. 
TABLE  V 
Presensitization of H-2  ~/b Mice with H-2  bib FV Leukemia Cells Does Not Increase Incidence of 
Recovery 
Group  Donor of FV leukemia cells*  Recipient:[:  Recovered/total§  P valuelt 
I  H-2  hm  H-2  a/b  2/14 (14%)  >0.1 
II  H-2  a/h  H-2  ~/b  1/13 (8%)  >0.1 
III  No cells transferred¶  H-2  a/h  2/10 (20%)  -- 
IV  H-2  b/b  H-2  hI"  12/14  (86%)  <0.01 
* Donor mice (C57BL/10Sn X A.BY)FI H-2  b/b or (BI0.A × A.BY)FI H-2  a/h were given 1,000 FFU 
FV-B intravenously.  8 d after FV inoculation spleens  were removed and single  cell suspensions 
were treated with anti-Thy-1 plus C' as described  in Materials and Methods. 
:~ (BI0.A X A.BY')FI recipient mice were given 40 >  106 viable Thy-l-depleted FV leukemic spleen 
cells from appropriate donors.  4 h later all recipients  received 500 FFU of FV-B intravenously. 
§ Number of mice recovering from FV splenomegaly over total number of mice. 
l[ P value as compared to control group III. 
¶ Control group of sex- and age-matched (B10.A × A.BY)FI H-2  a/b mice received only virus. 
were presumably  rejecting FV-transformed  autologous cells. FV-infected H-2  a/b mice 
were  capable  of rejecting  all  three  congeneic  leukemia  cell  types  (Table  III).  The 
rejection of FV-induced  leukemia cells of the H-2  a/a,  H-2  a/b, and  H-2 b/b genotype by 
FV-infected  H-2  ~/b mice indicated  that  effector mechanisms  responsible  for rejection 
of FV leukemia cells by H-2  a/b mice were operative against  all three H-2 genotypes of 
FV  leukemia  cells.  The  H-2  genotype  of the  FV  leukemia  cell did  not  influence  its 
susceptibility  to in vivo mechanisms mediating the rejection of FV leukemia cells. 
Transfer of Resistance  to  FV-induced Splenomegaly  by  Neonatally  Tolerant  H-2 bib  Spleen 
Cells.  Because  the  H-2  type  of the  erythroleukemia  cell  lines  used  in  the  previous 
experiments  did  not  influence  their  rejection,  we  considered  the  possibility  that 
nonleukemic spleen and  bone marrow  cells of differing H-2 types could vary in their 
influence  on  recovery  from  FV  leukemia.  To  study  whether  potential  anti-FV 
leukemia effector mechanisms  in  H-2 b/b mice were superior to those in  H-2  a/b or H- 
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cell  transfer experiments were performed using unirradiated  H-2  ~/b recipients.  After 
inoculation  with  FV,  unirradiated  H-2  ~/b  recipient  mice received spleen  and  bone 
marrow cells from H-2  b/b and H-2  ~/~ mice made neonatally tolerant to H-2  a/b antigens 
to avoid a lethal graft vs. host reaction. 
When tolerant H-2  b/b (high recovery) spleen and bone marrow cells were injected 
into  H-2  "/b mice,  these  cells  were  capable of causing increased  recovery from  FV- 
induced splenomegaly (Table IV). In a  reciprocal experiment, cells  from tolerant H- 
2  ~/~ (low recovery) mice did not mediate recovery from FV-induced splenomegaly in 
H-2  ~/b recipients. Because the majority of leukemia cells in the unirradiated recipients 
were of the H-2  a/b genotype (Table IV), these experiments demonstrated that H-2  a/b 
FV  leukemia  cells  were  readily  rejected  in  vivo after  transfer  of spleen  and  bone 
marrow cells  from H-2  b/b mice but not after transfer of spleen and bone marrow cells 
from H-2  ~/~ mice. These results offered strong evidence in support of the interpretation 
that H-2-associated recovery effect seen in FV leukemia operated via cells involved in 
the immune response to the leukemia rather than  at  the level  of the leukemia cells 
themselves. 
Presensitization  of H-2 a/b  Mice  with  H-2 b/b  Leukemic  Spleen  Cells.  An  alternative 
explanation  for the  above results  is  possible.  If erythroleukemia cells  of the  H-2  b/b 
genotype were more immunogenic than those of the H-2  ~/b or H-2  ~/a genotypes, then 
perhaps FV-transformed cells  derived from the donor H-2  b/b population could have 
induced a  stronger or more rapid specific immune response to FV leukemia cells  of 
both donor and recipient origin leading to an increased incidence of recovery. To test 
this possibility, we inoculated H-2  a/b mice with H-2  b/b or H-2  ~/b FV leukemic spleen 
cells and cell-free FV, and the course of leukemia was followed. Because all recipients 
received a  defined dose of cell-free virus, it was possible to ascribe any differences in 
the incidence of recovery to differences in the H-2 genotype of the sensitizing cell and 
not  to  any variation  in  the  amount  of cell-associated  virus  transferred.  Donor cell 
populations  were  pretreated  with  an  anti-Thy-1  reagent  and  C'  to  eliminate  T 
lymphocytes, which could contribute either to a graft vs. host reaction or to an anti- 
FV immune response. The results indicated that transfer of 40 ×  106 H-2  b/b leukemic 
spleen cells  did not result in an increased incidence of recovery from leukemia in H- 
2  ~/b mice (Table V). Thus, H-2  b/b leukemia cells  did not appear to exhibit enhanced 
immunogenicity leading  to recovery from  leukemia  in  this  situation.  These  results 
also supported our original interpretation that  nonleukemic H-2  b/b spleen and bone 
marrow cells were responsible for the increased recovery seen in Table IV. 
Discussion 
In this paper, the H-2 genotype of nonleukemic effector cells of the spleen and bone 
marrow  appeared  to  account  for  the  differences  in  recovery  from  FV  leukemia 
previously mapped  to  the  H-2D subregion  (3,  4).  In irradiation  chimeras,  the  H-2 
genotype  of the  donor  spleen,  bone  marrow,  and  fetal  liver  cells  influenced  the 
incidence of recovery from FV leukemia, whereas the H-2 genotype of the irradiated 
recipient  did not.  Heterozygous H-2  a/b mice recovering from primary FV leukemia 
generated effector mechanisms that rejected FV leukemia cells of three different H-2 
genotypes with  equal  efficiency. Furthermore,  immunocompetent high-recovery H- 
25/5 spleen and bone marrow cells  led to enhanced recovery from leukemia in H-2  a/b 
mice. This result suggested that H-2  a/b leukemia cells were eliminated by effector cells WILLIAM J.  BRITT AND BRUCE CHESEBRO  1801 
derived  from  the  transferred  H-2  b/b  donor  cells.  This  observation  was  somewhat 
surprising in that the number of transferred H-2  b/b cells was small compared to the 
number of spleen cells in the unirradiated  H-2  a/b recipient.  Presumably, the passive 
transfer of these cells into unirradiated  recipients was effective because of the strong 
antigenic stimulus provided by the presence of FV-infected cells in these recipients. 
Recovery did  not  appear  to  be a  result  of allogeneic  H-2-specific graft  vs.  host 
reaction because H-2  a/b mice that had received neonatally tolerant  H-2  b/b cells and 
had  recovered  from  FV  leukemia  were  normal  in  appearance  and  exhibited  no 
evidence  of graft  vs.  host  disease  at  >120  d  post-cell  transfer.  The  reciprocal  cell 
transfer in which H-2  a/~ spleen and bone marrow cells tolerant to H-2  "/b were given 
to H-2  ~/b mice did not increase the incidence of recovery in recipient mice. Because 
tolerance to H-2  a/b was determined  by the same criteria in  both  H-2  b/b and  H-2  a/a 
donor mice, it was unlikely  that  an allogeneic anti-H-2 graft vs.  leukemia reaction 
occurred  in  one  chimera  but  not  in  the  other.  Because  our  results  indicated  that 
H-2  b/b cells tolerant to H-2  a could mediate recovery from FV leukemia, cross-reactivity 
between  H-2  a  alloantigens  and  FV-induced  antigens  could  not  explain  the  low 
recovery incidence previously noted in H-2  ~/~ and H-2  ~/b mice (4). 
Although  immunosuppression has been a  prominent  finding during FV leukemia 
in many mouse strains (10,  11), we have observed strong humoral immune responses 
to  FV  antigens  in  the  Fa  congenic  mice used  in  the  present  study  (12).  Humoral 
immunity in this model appeared to be influenced  by a  single non-H-2 gene,  Rfv-3 
(12).  The  results  of  the  present  experiments  suggest  that  immunosuppression  of 
humoral  or cellular immune  mechanisms was not  responsible for the  low recovery 
incidence seen in H-2  a/b mice because H-2  b/b effector cells were able to develop and 
function adequately in the H-2  ~/b splenic environment even after high FV inoculation 
doses. 
The  mechanism  through  which  H-2  influences  recovery  from  FV  leukemia  is 
unknown. T  lymphocytes are required because neonatally thymectomized mice of the 
high-recovery H-2  b/b genotype have a  low incidence of recovery (W. J.  Britt and B. 
Chesebro.  Manuscript  in preparation.).  The most consistent finding associated with 
recovery from FV leukemia is the appearance of anti-FV CTL in recovered mice (6). 
However, because anti-FV CTL can be demonstrated in both low- and high-recovery 
strains, a  genetically determined inability to produce anti-FV CTL does not explain 
the difference in the incidence of recovery seen in congeneic mice of differing H-2D 
(Rfv-l) genotypes (6).  A more likely explanation would be a  difference in the rate of 
production  of anti-FV  CTL  in  mice of different  H-2  genotypes.  Mice  of the  high 
recovery H-2  b/b genotype might  generate anti-FV CTL earlier in  the course of the 
disease as compared to low recovery H-2  a/b or H-2  ~/a mice. Thus, a high incidence of 
recovery from FV leukemia might be the result of an early CTL response at a  time 
when  the leukemia cell burden  is low and  the elimination  of leukemia cells can be 
accomplished. This mechanism would account for the increased incidence of recovery 
seen in H-2  ~/b mice given a low dose of FV (4). A lower dose of virus results in a later 
attainment of maximum splenomegaly and might allow generation of anti-FV CTL 
in H-2  a/b mice at a  time when the leukemia cell number is lower. 
The H-2 complex has been shown to exert control over the generation of CITL in 
the H-Y and trinitrophenyl systems (13,  14). Zinkernagel et al. (15) have reported the 
influence of the  H-2D subregion  on  the in  vivo generation of vaccinia and  Sendal 1802  H-2 INFLUENCE ON  RECOVERY FROM FRIEND LEUKEMIA 
virus-specific CTL.  In  contrast  to  previously  reported  immune  response  (Ir)  gene 
phenomena  (16),  these  virus-specific H-2D  region  CTL-Ir genes were  inherited  as 
recessive traits (15). Because the H-2D (Rfv-l)-associated recovery from FV leukemia 
was inherited  in  a  recessive or gene-dose fashion  (4),  it  appeared  possible that  this 
gene could operate like a CTL-Ir gene in controlling the production of anti-FV CTL. 
Previously it has been postulated that H-2-1inked CTL-Ir genes may operate through 
the  influence  of the  thymic  epithelium  on  CTL  precursors  during  ontogeny  (17). 
Thus,  the  thymic  epithelium  may  influence  the  CTL  response  by control  of H-2 
restriction  of CTL. Our findings that  fetal liver of the H-2  b/b genotype produced a 
high incidence of recovery even after maturation in an irradiated H-2  a/b host  (Table 
I) did not support the interpretation that the thymic epithelium had a major influence 
on  the  in  vivo response to FV  leukemia. This observation was, however, consistent 
with previous data using fetal liver irradiation chimeras in which the Ir gene control 
of the  response  to  poly(L-tyrosine,L-glutamic  acid)-DL-alanine--L-iysine was  deter- 
mined  at  the  level  of differentiation  of fetal  liver  and  was  not  influenced  by  the 
thymic epithelium present during differentiation (18). 
Our results are in contrast with reports which have suggested the H-2 genotype of 
the FV  leukemia cell was important  in determining the incidence  of recovery from 
FV (19). One group of investigators noted that FV selectively associated with the H- 
2D  b gene product (20,  21) and postulated that this association might produce a better 
target  for anti-FV CTL (19).  Anti-FV CTL might  then  more readily eliminate  FV 
leukemia cells of the H-2D  b genotype and lead to an increased incidence of recovery 
(19).  Although  H-2D  b expression by leukemia cells may be necessary for maximum 
CTL  activity  (22)  and  maximum  recovery,  the  difference  in  recovery  incidence 
between H-2  b/b and H-2  a/b mice, both of which possess an H-2D  b allele suggests that 
H-2D  b expression by leukemia cells is not sufficient for recovery (3). The present cell- 
transfer experiments supported this interpretation and appeared to indicate that the 
association of FV with the H-2D  b gene product on leukemia cells did not explain the 
influence of the H-2D region on recovery from leukemia. 
Natural killer  (NK) cells or hemopoietic histocompatibility (Hh) resistance mech- 
anisms may also play a  role in recovery from FV leukemia. These mechanisms have 
been shown  to  recognize  FV  leukemia cells,  and  both  appear to be  influenced  by 
genes mapping to the H-2D region  (23, 24).  However, our preliminary data suggest 
that NK activity does not differ between the high and low recovery F1 congenic mice 
(H-2  b/b,  H-2  a/b,  and  H-2  "/~)  used  in  this  system  (W.  J.  Britt  and  B.  Chesebro. 
Manuscript in preparation.). Furthermore, both Hh- and NK-mediated resistance to 
bone  marrow  and  tumors  are  only  effective  against  low  numbers  of cells  in  the 
challenge  inoculum  (25),  whereas  recovery  from  the  massive splenomegaly  of FV 
leukemia requires elimination of a large number of leukemia cells. Although it appears 
that  anti-FV  antibody and  natural  resistance  mechanisms such as NK cells do not 
account  for  the  influence  of H-2  or  recovery  from  FV  leukemia,  these  and  other 
resistance  mechanisms  could  still  contribute  to  the  incidence  of recovery.  In  the 
present system, cytotoxic anti-FV antibody seems to be necessary but  not sufficient 
for recovery (5,  12). Antibody to FV could augment anti-FV CTL activity either by 
direct cytolysis of FV leukemia cells or by decreasing ceil-free FV antigens that could 
potentially  block  anti-FV  CTL.  Thus,  the  complex  process  of recovery  from  FV 
leukemia probably requires anti-FV antibody and anti-FV CTL operating simuha- WILLIAM J.  BRITT  AND  BRUCE  CHESEBRO  1803 
neously. The importance of additional mechanisms of resistance, such as NK cells, to 
the overall process of recovery is currently being studied. 
Summary 
H-2D  (Rfv-1)-associated  control  of recovery  from  FV  leukemia  was  studied  in 
congenic mice. In irradiation chimeras, the high recovery phenotype was transferred 
by cells of the  spleen,  bone  marrow,  and  fetal  liver.  Furthermore,  in  cell  transfers 
using  unirradiated  recipients,  spleen  and  bone  marrow  cells  of the  high-recovery 
genotype were able to mediate recovery from  leukemia in  mice of the low-recovery 
genotype.  Thus,  the  H-2D  (Rfv-l)  influence  on  recovery  appeared  to  operate  via 
nonleukemic cells of the spleen and bone marrow rather than via leukemic cells. The 
specific nonleukemic cell type(s)  involved in  recovery remains  unknown.  However, 
the mechanism appears to be complex and probably involves both anti-FV antibody 
and FV-specific cytotoxic T  lymphocytes. 
Received  for publication 14July 1980. 
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